You have full access to this article via your institution. A cancer diagnosis of any kind portends a rough road ahead, but that has been especially true of lung cancer. The World Health Organization estimates that 1.8 million people died from lung cancer in 2022. That is around 900,000 more deaths than were caused by the next most lethal malignancy: colorectal cancer.
Lung cancer has long been associated with tobacco smoking. As smoking has fallen out of favour over the past few decades, it might be expected that the disease would lose its grim primacy. But people who have never smoked get lung cancer too — in Asia, this group accounts for around 30% of cases. A large proportion of people who have never smoked but have the disease are women.
This has highlighted a difference between men and women that has led some researchers to conclude that lung cancer in women is a distinct condition. Early detection is key to improving the outcomes of lung cancer treatment, and people who are at high risk of developing the disease can benefit from routine scans to catch tumours early. But health agencies are grappling with who should qualify for such screening. Young people and non-smokers, for example, are typically not eligible, and, as a result, are often diagnosed too late for treatment to be effective.
Although the picture overall remains dire, rays of hope are filtering through. New drugs that target specific cancer-causing mutations are proving impressively effective. One drug approved in 2025, for example, slows tumour growth and stops the mass forming blood vessels that it needs to sustain itself. Researchers are also refining their understanding of how certain lung cancer cells resemble neurons — an insight that could lead to better therapies for lung cancers that spread to the brain.
Globally, the burden of lung cancer is not evenly distributed. Parts of Asia are disproportionately affected, in part, because of the continuing prevalence of smoking there. And people of African descent all over the world find themselves at a particular disadvantage. We are pleased to acknowledge the financial support of MSD and Daiichi Sankyo in producing this Outlook.
As always, Nature retains sole responsibility for all editorial content. This article is part of Nature Outlook: Lung cancer, a supplement produced with financial support from Daiichi Sankyo and MSD. Nature maintains full independence in all editorial decisions related to the content. Drugs that boost immunity are making lung cancer less deadly
AI and simple blood tests could catch lung cancer earlier Good, but you could still get lung cancer How the connection between lung cancer and the brain could lead to better treatments Global lung cancer burden shifting to middle-income countries
Why Africa’s low rate of lung cancer is an illusion Partner content: AI could clear a path for precision medicine in lung cancer Global lung cancer burden shifting to middle-income countries Global lung cancer burden shifting to middle-income countries
Good, but you could still get lung cancer Good, but you could still get lung cancer The Heidelberg University Biochemistry Center (BZH) is seeking to fill a Full Professorship (W3) for “Biochemistry” (f/m/d) as soon as possib... Faculty/Independent PI positions at Shenzhen Bay Laboratory
The Chinese University of Hong Kong, Shenzhen - School of Science and Engineering CUHK-Shenzhen invites applications for faculty positions at all ranks to join our rapidly expanding AI ecosystem. Located in southern China's Guangdong Province, Shenzhen sits on the eastern shore of the Pearl River Estuary. It shares a southern border with Hong Kong and faces the South China Sea, forming a core geographic hub of the Greater Bay Area.
We are seeking outstanding scientists to lead vigorous independent research programs focusing on all aspects of chemical biology including...
